CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin[TM].
Business Wire › March 17, 2010
Linked as:
Extract
CPEX Pharmaceuticals Announces Preliminary Results from its Phase 2a Clinical Trial of Nasulin[TM].
EXETER, N.H. -- CPEX Pharmaceuticals Inc. (NASDAQ: CPEX) today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company's nasal insulin product, Nasulin[TM]. The study was designed to evaluate the efficacy and safe...
See the full content of this document
Sponsored links
